We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+37.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.9B
AUM Growth
+$644M
(+15%)
Cap. Flow
-$263M
Cap. Flow
% of AUM
-5.37%
Top 10 Holdings %
Top 10 Hldgs %
40.38%
Holding
132
New
23
Increased
22
Reduced
35
Closed
25
Avg Time Held Equity + Options
8.6
quarters
Top 10 Avg Time Held Equity + Options
7
quarters
Top 20 Avg Time Held Equity + Options
8.2
quarters
Avg Time Held Equity only
8.7
quarters
Top 10 Avg Time Held Equity only
7
quarters
Top 20 Avg Time Held Equity only
8.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$41.7M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$37.3M |
| 3 |
Elevance Health
ELV
|
+$33.5M |
| 4 |
HELP
Helus Pharma Inc. Common Stock
HELP
|
+$24.7M |
| 5 |
Bruker
BRKR
|
+$23.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$125M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$65.8M |
| 3 |
Exact Sciences
EXAS
|
+$51.6M |
| 4 |
Axsome Therapeutics
AXSM
|
+$38.9M |
| 5 |
SI-BONE Inc
SIBN
|
+$38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.3% |
| 2 | Miscellaneous | 0.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
RAPT Therapeutics
RAPT
| $55.6M | 1.14% |
1,642,891
+556,273
| +51% | +$17.3M |
2024 Q4
4 quarters
|
|
27
Corvus Pharmaceuticals
CRVS
$791M
| $55.2M | 1.13% |
7,165,006
| – | – |
2016 Q1
39 quarters
|
|
28
United Therapeutics
UTHR
$23.5B
| $51.3M | 1.05% |
105,200
-9,700
| -8% | -$4.52M |
2025 Q3
1 quarter
|
|
29
Abivax
ABVX
$7.4B
| $49.6M | 1.01% |
367,900
-12,100
| -3% | -$1.32M |
2025 Q3
1 quarter
|
|
30
Roivant Sciences
ROIV
$24.2B
| $47.5M | 0.97% |
2,190,907
-523,891
| -19% | -$10.3M |
2025 Q2
2 quarters
|
|
31
DELISTED
Crinetics Pharmaceuticals
CRNX
| $46.5M | 0.95% |
999,000
-100,000
| -9% | -$4.45M |
2018 Q3
29 quarters
|
|
|
32
Axsome Therapeutics
AXSM
$8.2B
| $46.2M | 0.94% |
253,121
-278,679
| -52% | -$38.9M |
2025 Q1
3 quarters
|
|
33
EyePoint Inc
EYPT
$269M
| $45.1M | 0.92% |
2,468,314
+672,314
| +37% | +$9.53M |
2025 Q3
1 quarter
|
|
|
RNAM
34
DELISTED
Avidity Biosciences
RNAM
| $44.7M | 0.91% |
619,530
-1,019,356
| -62% | -$65.8M |
2024 Q1
7 quarters
|
|
35
Neurocrine Biosciences
NBIX
$13.7B
| $44.6M | 0.91% |
314,240
-39,400
| -11% | -$5.71M |
2018 Q1
31 quarters
|
|
36
Dyne Therapeutics
DYN
$2.88B
| $43.1M | 0.88% |
2,202,184
-112,000
| -5% | -$2.12M |
2024 Q1
7 quarters
|
|
|
37
Bristol-Myers Squibb
BMY
$116B
| $41.8M | 0.85% |
+775,000
| New | +$37.3M |
2025 Q4
0 quarters
|
|
|
38
Pfizer
PFE
$161B
| $41.2M | 0.84% |
+1,652,900
| New | +$41.7M |
2025 Q4
0 quarters
|
|
39
Trevi Therapeutics
TRVI
$1.78B
| $39.9M | 0.82% |
3,190,700
-117,700
| -4% | -$1.36M |
2025 Q1
3 quarters
|
|
40
Neuropace
NPCE
$441M
| $37.2M | 0.76% |
2,406,335
-207,849
| -8% | -$2.78M |
2021 Q2
18 quarters
|
|
41
Ascendis Pharma A/S
ASND
$14.7B
| $36.7M | 0.75% |
171,977
-19,928
| -10% | -$4.12M |
2025 Q2
2 quarters
|
|
|
42
DELISTED
Exact Sciences
EXAS
| $35.7M | 0.73% |
351,716
-642,900
| -65% | -$51.6M |
2024 Q1
7 quarters
|
|
43
Mineralys Therapeutics
MLYS
$1.81B
| $35.6M | 0.73% |
980,400
-489,094
| -33% | -$19.6M |
2025 Q2
2 quarters
|
|
|
44
Elevance Health
ELV
$92B
| $34.7M | 0.71% |
+99,100
| New | +$33.5M |
2025 Q4
0 quarters
|
|
45
DELISTED
Forte Biosciences
FBRX
| $32.6M | 0.67% |
1,196,955
| – | – |
2024 Q4
4 quarters
|
|
46
Prelude Therapeutics
PRLD
$283M
| $31.6M | 0.65% |
10,909,256
| – | – |
2020 Q3
21 quarters
|
|
|
HELP
47
Helus Pharma Inc. Common Stock
HELP
$756M
| $31.4M | 0.64% |
+3,840,500
| New | +$24.7M |
2025 Q4
0 quarters
|
|
48
Oric Pharmaceuticals
ORIC
$1.19B
| $29.8M | 0.61% |
3,641,756
| – | – |
2025 Q1
3 quarters
|
|
49
Krystal Biotech
KRYS
$9.59B
| $29.5M | 0.6% |
119,800
+17,055
| +17% | +$3.59M |
2023 Q4
8 quarters
|
|
50
Praxis Precision Medicines
PRAX
$6.8B
| $27.9M | 0.57% |
+94,500
| New | +$17.6M |
2025 Q4
0 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q4 2025 Portfolio in Review
As of Q4 2025, OrbiMed held 132 positions worth $4.9B, up 15% from $4.26B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $263M in Q4 2025, closing 25 positions and reducing 35 holdings. Its most notable exit was SI-BONE Inc, an estimated $38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Pfizer worth $41.2M.
- OrbiMed's largest Q4 2025 buy was Pfizer: 1,652,900 shares worth $41.2M.
- OrbiMed added most to RAPT Therapeutics in Q4 2025, an estimated $17.3M increase.
- OrbiMed's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $125M.
- OrbiMed fully exited SI-BONE Inc in Q4 2025, selling an estimated $38M.
- OrbiMed's ten largest holdings make up 40% of its $4.9B portfolio in Q4 2025.
- OrbiMed opened 23 new positions and closed 25 in Q4 2025.
- OrbiMed's portfolio value rose 15% quarter-over-quarter to $4.9B.
Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.